Lantheus Holdings, Inc. reported a revenue of $377.3 million for the first quarter of 2026, reflecting a 1.2% increase from $372.8 million in the same period of 2025. The company's net income rose significantly to $118.4 million, or $1.80 per diluted share, compared to $72.9 million, or $1.02 per diluted share, in the prior year, marking a 62.3% increase in profitability. This growth in net income was attributed to higher revenues from newly acquired products and a gain from the sale of its SPECT business, which contributed $59.3 million to non-operating income.
The financial performance was bolstered by the introduction of Neuraceq, which generated $35.4 million in revenue following Lantheus's acquisition of Lantheus Biosciences in July 2025. Additionally, DEFINITY sales increased by 6.8% to $84.6 million. However, revenue from PYLARIFY, the company's flagship product, decreased by 6.5% to $240.9 million, primarily due to a reduction in net sales price. The company also noted a shift in revenue classification following the divestiture of its SPECT business, which had previously contributed to revenue figures.
In terms of operational developments, Lantheus completed the sale of its SPECT business on January 1, 2026, receiving approximately $130.5 million in total consideration, including $31.4 million in cash. This strategic move allowed the company to focus on its core radiopharmaceutical business, particularly in oncology, neurology, and cardiology. The company has also been actively expanding its product offerings, with the FDA's recent approval of PYLARIFY TruVu, a new formulation expected to enhance product stability and manufacturing efficiency.
Lantheus's total assets increased to $2.35 billion as of March 31, 2026, up from $2.23 billion at the end of 2025, driven by cash and cash equivalents rising to $498.6 million. The company reported a total stockholders' equity of $1.21 billion, reflecting a significant increase from $1.09 billion at the end of the previous fiscal year. The company’s employee headcount has also grown, reflecting its expansion efforts and the integration of acquired businesses.
Looking ahead, Lantheus remains focused on enhancing its product pipeline and expanding its market presence. The company anticipates continued growth from its existing products and new launches, including the upcoming commercialization of PYLARIFY TruVu. The management expressed confidence in its strategic direction, emphasizing the importance of maintaining competitive advantages in the evolving radiopharmaceutical landscape.
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a leading provider of radiopharmaceuticals and diagnostic imaging products. Its core activities include developing, manufacturing, and marketing radiopharmaceuticals for oncology and cardiology, such as PYLARIFY and DEFINITY. The company serves healthcare providers worldwide, offering products that improve disease detection, characterization, and patient outcomes through advanced imaging and therapeutic solutions. Its business model combines product sales, strategic partnerships, and clinical development.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.